



EFQM

Recognised for Excellence
5 Star - 2018

Guideline

Table 3. Clinical guidelines for children aged 6–10 years with myopia > 1.0 D and documented myopia progression > 0.5 D per year

| | | |
|-----------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------|
| Treat children with Atropine 0.01% for 2 years | | |
| Good response: almost no myopic progression (<0.5 D over second year) | Moderate response: myopic progression of 0.5 D to 1.0 D over second year | Poor response: myopic progression >1.0 D over second year |
| Taper and stop Atropine | Continue Atropine 0.01% for a further 1–2 years, then taper and stop Atropine | May be a non-responder. Consider taper and stop Atropine |
| Follow subject for a year post stopping Atropine | | |
| Recommence Atropine if significant rebound and continue review | | |

Source: modified from the ATOM2 study (85).